Don Tracy, Associate Editor

Kevin Hagan, CEO, Pan Foundation, discusses central concerns for patient assistance programs as changes to Medicare and the Inflation Reduction Act take effect.

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug conjugates for the treatment of cancer.

Jen Butler, chief commercial officer, Pleio, discusses the importance of balancing technology and personalization in patient support.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

Jen Butler, chief commercial officer, Pleio, discusses how personalization, connectivity, technology, and proactive support are working to evolve patient engagement strategies.

Jen Butler, chief commercial officer, Pleio, discusses the effectiveness of peer-to-patient outreach when starting specialty medications.

Jen Butler, chief commercial officer, Pleio, discusses how the company’s GoodStart programs help patients navigate specialty pharmacies.

Jonathan James, CEO, Hope Charities, discusses how, despite policy advancements, millions of people still face barriers to healthcare access.

Jonathan James, CEO, Hope Charities, discusses the challenge of nonprofits securing sustainable funding while ensuring patients are aware of available assistance.

Jonathan James, CEO, Hope Charities, discusses the critical importance of maintaining access to life-saving medications for patients with rare diseases to lead productive lives.

Jonathan James, CEO, Hope Charities, discusses reimbursement challenges and barriers to care in patients requiring life-saving medications.

Ron Lanton, Partner, Lanton Law, examines the legal and economic impacts of reciprocal tariffs on the pharma supply chain, including potential disruptions and increased drug costs.

Lisa Arthurs, VP, trade, Two Labs, discusses a roundtable discussing women in trade as well as empowering future leaders.

Jon Hamrick, partner, Curatio Scientia Advisors, discusses upcoming industry challenges at this year's Trade & Channel Strategies Conference in Philadelphia.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the difference between return on invested capital in pharma compared to other organizations.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses observations in enterprise value growth and enterprise value-to-sales ratios among top biopharmaceutical companies.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment," and upcoming industry challenges.

Kevin O’Meara discusses how patient service teams influence adherence from Direct-to-Patient models.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the breakout session at Trade & Channel Strategies in Philadelphia.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year.

The proposal aims to reduce out-of-pocket costs for a number of weight loss medications by 95%.

JAMA study indicates Canada may have a more resilient drug supply chain or different thresholds for reporting and responding to issues compared with the United States.

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses examples of how effective communication can resolve supply chain issues.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses how to handle opposing concerns between supply chain teams and offers communication solutions.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses critical conversations that supply chain teams and partners must partake in during API sourcing at LogiPharma USA 2024.